Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSTCARD - GETUG P13
2024-513207-13-00Phase 2Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in prostate cancer (PCa) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Disease progression-free survival (composite of PSA, local, distant progression or death). Planned start Jul 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-513207-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513207-13-00.